Brii Biosciences Employees

Brii Biosciences had 96 employees as of June 30, 2025. The number of employees decreased by 2 or -2.04% since the number was reported on December 31, 2024.

Employees

Change

-2

Growth

-2.04%

Revenue / Employee

$41,839

Profits / Employee

-$546,285

Market Cap

132.91M

Employees Chart

Employees History

Date	Employees	Change (1Y)	Growth (1Y)
Jun 30, 2025	96	-2	-2.04%
Dec 31, 2024	98	-30	-23.44%
Dec 31, 2023	128	-18	-12.33%
Dec 31, 2022	146	33	29.20%
Dec 31, 2021	113	-	-

Related Stocks

Company Name	Employees
Silence Therapeutics	116
Vaxart	105
CytoDyn	13
Nuo Therapeutics	9
ZIVO Bioscience	7
Vicapsys Life Sciences	2
Cell Source	1

Employee Rankings

Brii Biosciences News

3 months ago - Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine - PRNewsWire
6 months ago - Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results - PRNewsWire
7 months ago - Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China - PRNewsWire
9 months ago - Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss - PRNewsWire
11 months ago - Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification - PRNewsWire
1 year ago - Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study - PRNewsWire
1 year ago - Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA - PRNewsWire
1 year ago - Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024 - PRNewsWire

More News